- Home
- RJF vs IQV Comparison
RJF vs IQV Comparison
Compare RJF & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RJF
- IQV
- Stock Information
- Founded
- RJF 1962
- IQV 1982
- Country
- RJF United States
- IQV United States
- Employees
- RJF N/A
- IQV N/A
- Industry
- RJF Investment Bankers/Brokers/Service
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- RJF Finance
- IQV Health Care
- Exchange
- RJF Nasdaq
- IQV Nasdaq
- Market Cap
- RJF 28.5B
- IQV 24.9B
- IPO Year
- RJF N/A
- IQV 2013
- Fundamental
- Price
- RJF $145.50
- IQV $153.21
- Analyst Decision
- RJF Buy
- IQV Buy
- Analyst Count
- RJF 12
- IQV 20
- Target Price
- RJF $157.64
- IQV $230.55
- AVG Volume (30 Days)
- RJF 1.4M
- IQV 2.1M
- Earning Date
- RJF 04-23-2025
- IQV 05-06-2025
- Dividend Yield
- RJF 1.37%
- IQV N/A
- EPS Growth
- RJF 25.51
- IQV 0.26
- EPS
- RJF 10.38
- IQV 7.35
- Revenue
- RJF $13,623,000,000.00
- IQV $15,497,000,000.00
- Revenue This Year
- RJF $10.57
- IQV $4.08
- Revenue Next Year
- RJF $6.01
- IQV $5.88
- P/E Ratio
- RJF $14.02
- IQV $20.96
- Revenue Growth
- RJF 13.88
- IQV 2.84
- 52 Week Low
- RJF $104.24
- IQV $135.97
- 52 Week High
- RJF $174.32
- IQV $252.88
- Technical
- Relative Strength Index (RSI)
- RJF 62.36
- IQV 47.11
- Support Level
- RJF $139.79
- IQV $143.65
- Resistance Level
- RJF $143.15
- IQV $156.31
- Average True Range (ATR)
- RJF 3.25
- IQV 5.56
- MACD
- RJF 1.41
- IQV 1.74
- Stochastic Oscillator
- RJF 87.98
- IQV 82.69
About RJF Raymond James Financial Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company supports more than 8,000 employee and independent contractor financial advisors across the United States, Canada, and the United Kingdom with over $1.5 trillion of assets under administration as of September 2024. Approximately 90% of the company's revenue is from the US and 70% is from the company's wealth-management segment.
About IQV IQVIA Holdings Inc.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.